Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 8 Apr 22 EFFECT Notice of effectiveness
-
11 Mar 22 POS AM Prospectus update (post-effective amendment)
- 10 Mar 22 POSASR Automatic shelf registration (post-effective amendment)
- 24 Jun 21 424B5 Prospectus supplement for primary offering
- 22 Jun 21 424B5 Prospectus supplement for primary offering
- 10 May 21 424B5 Prospectus supplement for primary offering
- 31 Jul 20 424B5 Prospectus supplement for primary offering
- 27 Jul 20 424B5 Prospectus supplement for primary offering
- 27 Jul 20 S-3ASR Automatic shelf registration
Filing view
External links
Exhibit 23.3
Consent of Independent Registered Public Accounting Firm
BioXcel Therapeutics, Inc.
New Haven, CT
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March 12, 2021, relating to the financial statements of BioXcel Therapeutics, Inc. appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
Stamford, CT
March 11, 2022